H.C. Wainwright raised the firm’s price target on Sangamo (SGMO) to $10 from $5 and keeps a Buy rating on the shares. The firm says the accelerated clinical development plan in Fabry disease may support an application filing in the first half of 2025.
Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
The Fly
Sangamo price target raised to $10 from $5 at H.C. Wainwright
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App